company background image
ADAP logo

Adaptimmune Therapeutics NasdaqGS:ADAP Rapporto sulle azioni

Ultimo prezzo

US$0.66

Cap. di mercato

US$162.8m

7D

12.8%

1Y

42.3%

Aggiornato

22 Nov, 2024

Dati

Dati finanziari dell'azienda +

Adaptimmune Therapeutics plc

NasdaqGS:ADAP Rapporto sulle azioni

Cap. di mercato: US$162.8m

Adaptimmune Therapeutics plc Concorrenti

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Adaptimmune Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$0.66
Massimo di 52 settimaneUS$2.05
Minimo di 52 settimaneUS$0.42
Beta2.25
1Variazione di 1 mese-15.71%
Variazione a 3 mesi-45.32%
Variazione di 1 anno42.28%
3Variazione a 3 anni-83.74%
Variazione a 5 anni-43.45%
Variazione dall'IPO-96.16%

Notizie e aggiornamenti recenti

Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

Nov 15
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Recent updates

Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

Nov 15
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

Sep 12

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jul 03

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Adaptimmune: Drug Approval Now Imminent?

Feb 02

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

Sep 20

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Aug 10
Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics

Aug 03

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

Jun 29

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

Jun 19

Adaptimmune Therapeutics: A Little More Patience May Be Profitable

Mar 06

Circling Back On Adaptimmune Therapeutics

Dec 15

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Dec 02
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming

Sep 29

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Aug 14
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Rendimenti per gli azionisti

ADAPUS BiotechsUS Mercato
7D12.8%2.4%2.2%
1Y42.3%16.2%31.7%

Ritorno vs Industria: ADAP ha superato il US Biotechs che ha restituito 16.2 % nell'ultimo anno.

Rendimento vs Mercato: ADAP ha superato il mercato US che ha restituito 31.7 % nell'ultimo anno.

Volatilità dei prezzi

Is ADAP's price volatile compared to industry and market?
ADAP volatility
ADAP Average Weekly Movement10.9%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di ADAP è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 11% ) di ADAP è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
2008449Ad Rawcliffewww.adaptimmune.com

Adaptimmune Therapeutics plc, azienda biofarmaceutica in fase clinica, fornisce nuove terapie cellulari principalmente a pazienti oncologici negli Stati Uniti e nel Regno Unito. L'azienda sviluppa SPEARHEAD-1, che è in fase II di sperimentazione clinica con ADP-A2M4 per il sarcoma sinoviale; SURPASS-3, che è in fase II di sperimentazione clinica con ADP-A2M4CD8 per i pazienti affetti da carcinoma ovarico resistente al platino; e SURPASS, che è in fase I di sperimentazione clinica in pazienti affetti da tumori della testa e del collo e uroteliali. L'azienda ha un accordo di collaborazione strategica e di licenza con Genentech, Inc. e F. Hoffman-La Roche Ltd per lo sviluppo di terapie personalizzate a base di cellule T allogeniche e allogeniche; un accordo di ricerca, collaborazione e licenza con Universal Cells, Inc.; collaborazioni di terze parti con Noile-Immune e Alpine Immune Sciences; e un accordo di alleanza strategica con il MD Anderson Cancer Center.

Adaptimmune Therapeutics plc Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Adaptimmune Therapeutics con la sua capitalizzazione di mercato?
ADAP statistiche fondamentali
Capitalizzazione di mercatoUS$162.81m
Guadagni(TTM)-US$44.52m
Ricavi(TTM)US$175.04m

1.0x

Rapporto P/S

-3.8x

Rapporto P/E

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ADAP Conto economico (TTM)
RicaviUS$175.04m
Costo del fatturatoUS$71.00m
Profitto lordoUS$104.05m
Altre speseUS$148.56m
Guadagni-US$44.52m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)-0.17
Margine lordo59.44%
Margine di profitto netto-25.43%
Rapporto debito/patrimonio netto62.3%

Come si è comportato ADAP nel lungo periodo?

Vedi performance storica e confronto